Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for New Horizon Health's Days Payable or its related term are showing as below:
FRA:6YZ's Days Payable is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 67.97 * Ranked among companies with meaningful Days Payable only.
New Horizon Health's Days Payable
declined
from Jun. 2022 (223.94) to Jun. 2023 (181.41).
It may suggest that New Horizon Healthaccelerated paying its suppliers.
New Horizon Health Days Payable Related Terms
New Horizon Health Days Payable Historical Data
* Premium members only.
The historical data trend for New Horizon Health's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, New Horizon Health's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
New Horizon Health Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, New Horizon Health's Days Payable distribution charts can be found below:
* The bar in red indicates where New Horizon Health's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
New Horizon Health's Days Payable for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
New Horizon Health (FRA:6YZ) has a Days Payable of 181.41 as of Jun. 2023. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on New Horizon Health and its competitors.
Is New Horizon Health's Days Payable too high?
New Horizon Health's current Days Payable is 181.41. The Medical Devices & Instruments industry median Days Payable is 67.97. New Horizon Health's value of 181.41 is 166.9% above this industry median. Overall, New Horizon Health has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does New Horizon Health's Days Payable compare to ABT and SYK?
New Horizon Health's Days Payable of 181.41 can be compared against companies in the Medical Devices & Instruments industry. The industry median Days Payable is 67.97. New Horizon Health's value of 181.41 is 166.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.97, based on 794 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. New Horizon Health's current Days Payable of 181.41 is 166.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on New Horizon Health and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. New Horizon Health's current Days Payable is 181.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is New Horizon Health stock overvalued right now?
New Horizon Health (FRA:6YZ) has a current Days Payable of 181.41. The current Days Payable is 181.41 and 166.9% above the Medical Devices & Instruments industry median of 67.97. New Horizon Health's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For New Horizon Health (FRA:6YZ), the current Days Payable is 181.41 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
New Horizon Health Ltd is engaged in early cancer screening and in-home testing in China. The company has an early detection and cancer screening-focused pipeline of five products and product candidates with an emphasis on colorectal cancer screening. The company focuses on cancer prevention and cure through screening and early detection. It generates maximum revenue from ColoClear and Pupu Tube products.
35GF Score
Get the complete analysis for FRA:6YZ
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6YZ has been successfully added to your 
